- Acumen Powered by Robins Kaplan LLP®
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 17, 2024Emily Tremblay Named IP Rising Star by Euromoney in 2024 Women in Business Law Awards
-
June 17, 2024Three Robins Kaplan Partners Named BTI Client Service All-Stars
-
June 13, 2024Brendan Johnson Named South Dakota Trial Lawyer of The Year
-
June 27, 2024Sex Abuse Litigation
-
June 10-11, 20242024 Probate and Trust Law Section Conference
-
June 11, 2024FBA 2024 Federal Practice Seminar
-
June 2024Robins Kaplan Secures Landmark $7.75 Million Verdict in Aerosol Duster Misuse Case
-
June 2024To Seize or Not to Seize: Campus Protests and Police Uses of Force
-
June 2024Communicating Your Estate Plan: A Helpful Tool, Not a Fix-All
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Bayer Pharma AG v. Watson Labs., Inc.
A proposed combination will not render a patent obvious wherein the proposed combination includes changing the core structure of the lead compound.
May
Case Name: Bayer Pharma AG v. Watson Labs., Inc., Civ. No. 12-cv-517 (GMS), 2016 U.S. Dist. LEXIS 57888 (D. Del. May 2, 2016) (Sleet, J.)
Drug Product and U.S. Patent(s)-in-Suit: Staxyn® and Levitra® (vardenafil hydrochloride trihydrate); U.S. Patents Nos. 8,613,950 (“the ’950 patent), 6,362,178 (“the ’178 patent”), and 7,696,206 (“the ’206 patent”)
Nature of the Case and Issue(s) Presented: Watson asserted that that claims of the ’178 and ’206 patents were invalid as obvious based on a combination using sildenafil as the lead compound. Watson proposed that one of skill would have modified the structure of sildenafil to arrive at the claimed invention.
Bayer argued that one of skill would not have selected sildenafil as the lead compound because it had less desirable potency and selectivity than other compounds that were known at the time. Even if one of skill would have started with sildenafil, one of skill would not have a reasonable expectation of success in modifying sildenafil to achieve the claimed invention. Such modifications would have included changing the core structure of sildenafil, changing substituents, and preparing sildenafil as a hydrochloride salt as compared to a citrate salt.
The court agreed with Bayer that Watson had not proven by clear and convincing evidence that the asserted claims were obvious.
Why Bayer Prevailed: The district court agreed with Bayer that one of skill would not have chosen sildenafil as a lead compound to address the problem. There were well-known, better potency and selectivity PE5 inhibitors that one of skill would have chosen over sildenafil. The court noted that Watson’s expert’s reason for selecting sildenafil was based mostly on improper hindsight.
The court further agreed with Bayer that even if sildenafil were selected, significant modifications and choices would have been needed to be made to arrive at the claimed invention. In particular, the proposed combination would have required several alterations to the core structure of sildenafil. Those changes would have impacted the efficacy and biologic activity of the modified structure to eliminate any expectation of success based on studies regarding unmodified sildenafil.
Lastly, the court found that secondary considerations of non-obviousness favored Bayer. In particular, one of skill would not have expected vardenafil’s structure to be an effective PE5 inhibitor given the scope and content of the literature at the time. In addition, vardenafil demonstrated effectiveness in patients that were considered sildenafil non-responders. As such, vardenafil solved a long felt need.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.